HRTX - Heron Therapeutics: Changing Strategy After Disappointing Earnings

• Heron Therapeutics had a productive 2021 with several corporate and commercial achievements that will set the company up for future growth.
• Subsequently, Heron obtained approval for a substantially expanded indication only five months after launch.
• Furthermore, the company filed an NDA for a potential fourth commercial product, HTX-019, for postoperative nausea and vomiting "PONV", which has a PDUFA date in September of this year.
• Unfortunately, COVID-19 headwinds continue to hinder both cancer treatments and elective surgeries. This contributed to disappointing earnings and a subsequent sell-off in the share price.
• I believe HRTX is now discounted for its future prospects. As a result, I am switching to a DCA strategy. My buy target is $6.50 and Sell 1 is $9.46.

For further details see: